Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.
Copyright 2012 Cardium Therapeutics, Inc. All rights reserved.
Cardium Therapeutics®, Generx®, Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen®, Excellarate™, Osteorate™, MedPodium®, Appexium®, Linée®, Alena®, Cerex®, D-Sorb™, Neo-Energy®, Neo-Carb Bloc®, Neo-Chill™, and Nutra-Apps® are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.
Suntheanine® is a trademark of Taiyo, International, Inc.
(Other trademarks belong to their respective owners)
*Note: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Cardium Therapeutics, Inc.Selected Condensed Consolidated Results of OperationsThree months ended June 30,Six months ended June 30,2012201120122011Product sales$Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 Related medicine technology :1
-Cost of goods sold(6,096)-(11,551)-Gross profit7,078-22,101-Operating expensesResearch and development(424,734)(803,858)(1,589,333)(1,295,432)Selling, general and administrative(1,459,214)(1,173,536)(2,968,975)(2,461,421)Loss from operations(1,876,870)(1,977,394)(4,536,207)(3,756,853)Interest income (expense), net1,4231,6872,5674,336Change in fair value of derivative liabilities-212,40164,
. Cardium Announces Plans For Commercializaton Of Excellagen® In The Russian Federation2
. Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences3
. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion4
. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care5
. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths6
. Grant & Eisenhofer Represents Key Whistleblower in Justice Dept.s $1.04 Billion Civil Settlement with GlaxoSmithKline7
. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 20128
. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease9
. Frost & Sullivan: Developing Integration Capabilities Presents a Real Opportunity for Vendors in the European CIS Market10
. This Week: UBM Canon Presents an Online Event and Conference Dedicated to Emerging Trends in Medical Device Outsourcing/Contract Manufacturing11
. Berg Pharma presents at ASCO, poised to lead field in cancer metabolism with Phase II trials of BPM 31510